Lumateperone Alone for Bipolar Depression
About this title
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Read the official source — NCT02600494Researchers compared ITI-007 (Lumateperone) and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared ITI-007 (Lumateperone) and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 54 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 554
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT02600494
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · Rogers · Cerritos
52 more locations
- Culver City
- Garden Grove
- Lemon Grove
- National City
- Oakland
- Oceanside
- Orange
- Pico Rivera
- Riverside
- San Diego
- San Marcos
- Santa Rosa
- Colorado Springs
- Bradenton
- Fort Myers
- Jacksonville
- Lauderhill
- Miami
- North Miami
- Orlando
- Atlanta
- Chicago
- Hoffman Estates
- Lake Charles
- Baltimore
- Boston
- O'Fallon
- St Louis
- Las Vegas
- Berlin
- Cherry Hill
- Marlton
- Toms River
- Brooklyn
- Cedarhurst
- New York
- Rochester
- Staten Island
- Cincinnati
- Cleveland
- Dayton
- Garfield Heights
- Oklahoma City
- Allentown
- Norristown
- Philadelphia
- Memphis
- Austin
- Dallas
- Houston
- Petersburg
- Everett
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared ITI-007 (Lumateperone) and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Did this study involve medication?
Yes. The study involved medication, including ITI-007 (Lumateperone) and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
